What One Ought to Know in the Healthcare Sector: New Research on Amarin, Amedica, Amedisys, American CareSource, and AS&E
NEW YORK, February 12, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Amarin (NASDAQ: AMRN), Amedica (NASDAQ: AMDA), Amedisys (NASDAQ: AMED), American CareSource (NASDAQ: ANCI), and AS&E (NASDAQ: ASEI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
AMRN Research Report: ( http://get.analystsreview.com/pdf/?c=Amarin&d=12-Feb-2015&s=AMRN ),
AMDA Research Report: ( http://get.analystsreview.com/pdf/?c=Amedica&d=12-Feb-2015&s=AMDA ),
AMED Research Report: ( http://get.analystsreview.com/pdf/?c=Amedisys&d=12-Feb-2015&s=AMED ),
ANCI Research Report: ( http://get.analystsreview.com/pdf/?c=American-CareSource&d=12-Feb-2015&s=ANCI ),
ASEI Research Report: ( http://get.analystsreview.com/pdf/?c=AS%26E&d=12-Feb-2015&s=ASEI ).
============
--
Analyst Update: Clinical Data Presentation, Agreements, Impact of Regulatory Rulings, Appointment, and Stock Buyback Authorizations
Reviewed by: Rohit Tuli, CFA®
U.S. stocks closed effectively flat in a relatively quiet trading session on Wednesday, February 11, as investors fixed their eyes on the developments of an emergency meeting of the eurozone countries to discuss Greece's finances. S&P 500 closed flat at 2,068.53, the Dow Jones Industrial Average edged lower 0.04% to 17,862.14 and Nasdaq Composite moved up 0.3% to close at 4,801.18. The European markets closed lower as investors awaited the outcome of the crucial meeting over financial aid to Greece, part of the several meetings scheduled over the coming days to decide the future of financial aid to Greece. The Asian markets ended mostly higher following a firm finish of global stocks on the preceding day, as well as driven by hopes for a deal between Greece and its international creditors.
Amarin Corporation PLC (Amarin) presented new data and related analyses from the MARINE and ANCHOR phase 3 studies at the American Heart Association Scientific Sessions in Chicago. The data show that use of its Vascepa® (icosapent ethyl) capsules significantly reduced remnant-like particle cholesterol (RLP-C) levels - a cardiovascular risk factor in studied patient populations with triglyceride (TG) levels ≥ 200 mg/dL and ≥ 500 mg/dL.
Amedica Corporation (Amedica) alongwith InterMed Resources signed a purchase agreement with HealthTrust, to sell its entire line of silicon nitride interbody devices at a contracted price for distribution exclusively through InterMed Resources TN LLC to HealthTrust member facilities throughout the United States.
Amedisys Inc (Amedisys) announced that it expects the impact of the 2015 Medicare Home Health Prospective Payment System (HH PPS) Final Rule to be more moderate as compared to its prior expectations. In its announcement dated January, 15, 2015, the Company informed that earlier it expected an impact of -0.80% relative to 2014 Medicare pricing; however, after further analysis, the company now expects the 2015 pricing to be relatively unchanged from 2014.
American Caresource Holdings Inc. (American CareSource) appointed Anthony Levinson as its new CFO. Mr. Levinson, who has over twenty years of financial executive experience, over half of which has been in the healthcare industry, replaces Adam S. Winger, who has served as Interim Chief Financial Officer since December 31, 2014.
American Science and Engineering, Inc.'s (AS&E) Board of Directors has approved an expansion of the Company's current stock repurchase authorization from $35 million to $50 million. With this increase, approximately $44.4 million is available for stock repurchases under the authorization.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article